Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MUfGeY5kfGmxbjDBd5NigQ>? MlLoNE42yqEQvF2= MUOyOEBp NH[4Top4[XSnch?= NFLMe3hud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? NEHEOnozPTF{M{C4Ni=>
Eca109 NVjuc4l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCwMlUwOi53L{Wg{txO M{HpPFI1NzR6L{eyJIg> MkPle4F1\XJ? NWXYdlJpcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MYWyOVEzOzB6Mh?=
Eca109 NWW3VlNVTnWwY4Tpc44hSXO|YYm= MkmwNE42yqEQvF2= MWW2M|EzNzJ2IHi= MYT3ZZRmeg>? MnzzbY5pcWKrdIOgZ4VtdCCvaXfyZZRqd28EoB?= MoTONlUyOjNyOEK=
Eca109 M{X3RmZ2dmO2aX;uJGF{e2G7 MoTqNE42yqEQvF2= Mki4NlQhcA>? MVT3ZZRmeg>? MUfpcohq[mm2czDj[YxtKGmwdnHzbY9v NG\mW|YzPTF{M{C4Ni=>
Eca109 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LJW|AvPcLizszN NEHMRZozPCCq MUP3ZZRmeg>? MVnpcoR2[2W|IFeyM20h[XK{ZYP0JIlvKHSqZTDj[YxtKGO7Y3zl NXTaR5FzOjVzMkOwPFI>
Eca109 NHe1TmpHfW6ldHnvckBCe3OjeR?= NX7K[ZgzOC53L{Gg{txO MXiyOEBp MoDje4F1\XJ? NWDENlJV\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu|rqEMjDhcoQhVU2SMh?= Ml;pNlUyOjNyOEK=
SW1116  M{PV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vRTlAvPS9zL{KvOUDPxE1? M2\4OFQ5KGh? M3r6WmROW09? NX7H[m1[\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? MV:yOFg4PDJ6Nh?=
LOVO NVK3NIN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;PT3VuOC53L{GvNk82KM7:TR?= NYn6cHVZPDhiaB?= NYLG[WhTTE2VTx?= NY\JZ5VZ\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? M1HnWlI1QDd2Mki2
SW1116  M4DS[mZ2dmO2aX;uJGF{e2G7 MkDINVAh|ryP MnSzOFghcA>? MVTEUXNQ MXTpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> NVK3UZBEOjR6N{SyPFY>
LOVO NUPMR2gzTnWwY4Tpc44hSXO|YYm= MVixNEDPxE1? MVS0PEBp NH;XU21FVVOR NXPtR5dLcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk Ml7KNlQ5PzR{OE[=
SW1116  M2\1bWFxd3C2b4Ppd{BCe3OjeR?= M1jEd|ExKM7:TR?= NVvGXHNJPDhiaB?= NUHafI5MTE2VTx?= MmXo[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MmDKNlQ5PzR{OE[=
LOVO NF7IZ5VCeG:ydH;zbZMhSXO|YYm= MXmxNEDPxE1? NXfUbHJnPDhiaB?= NIG0dI1FVVOR NVroZWsy\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ M3q1XlI1QDd2Mki2
RPMI-8226 M{LSe2Fxd3C2b4Ppd{BCe3OjeR?= NVrvXpRbOS9{IN88US=> NVP1R|RPPDhxN{KvPVYhcA>? NGHFeHdFVVOR NXzRc3FUcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3S2dlI1QDN|MUC4
OPM-2  NIPT[4VCeG:ydH;zbZMhSXO|YYm= M2LZU|EwOiEQvF2= MWW3Nk86Pi9zMkCgbC=> NETVVW1FVVOR NEDTPXRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NID4VpAzPDh|M{GwPC=>
JJN3  MY\BdI9xfG:|aYOgRZN{[Xl? MnvlNE42NzFizszN NX;BS2xQOjRxNEigbC=> NIXjNFZFVVOR NELwXFlqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NFHEWJEzPDh|M{GwPC=>
NCI-H929  MV7BdI9xfG:|aYOgRZN{[Xl? M3jyelEwOiEQvF2= M1u5XlczNzl4L{GyNEBp NIm2PFlFVVOR NVfzbHk6cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M4\TPFI1QDN|MUC4
RPMI-8226 NHiwVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7PbpVuOS9{IN88US=> MlTENlQwPDhxN{KgbC=> NYfkOpVRTE2VTx?= NUjUSHM2[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NVLnVWZnOjR6M{OxNFg>
OPM-2  NIDuNIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rZ[FEwOiEQvF2= MlfnNlQwPDhxN{KgbC=> NV\UN2xwTE2VTx?= NXHyZXM6[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MV6yOFg{OzFyOB?=
JJN3  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPnOJYxNjVxMTFOwG0> MYiyOE81QC95MjDo NVTVUHRkTE2VTx?= NHnJU|Vi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MVWyOFg{OzFyOB?=
NCI-H929  NYnuWYhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPtTG91OS9{IN88US=> Mn34NlQwPDhxN{KgbC=> M4PidWROW09? NF7jTIFi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= M2rm[|I1QDN|MUC4
HeLa Mn:zT4lv[XOnIFHzd4F6 MojMT4k:OTByMPMAl|UxODBizszNJIZweiCqRV7UNS=> MnPlNlQ4QDByOUi=
HeLa MWnLbY5ie2ViQYPzZZk> NInqXJBMcT13Lk[gxtEhOC53IN88UUBnd3JiaFXOWFI> NUPOPGVXOjR5OECwPVg>
HeLa MoLOT4lv[XOnIFHzd4F6 MU\LbV0zOS54INMxJFMvOCEQvF2g[o9zKGiFTmSx M3:1fVI1PzhyMEm4
HeLa NVTKVmJxU2mwYYPlJGF{e2G7 MWXLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz NFq5NJEzPDd6MEC5PC=>
NB4 MVvGeY5kfGmxbjDBd5NigQ>? MVqyMlUwPS95LkWvNVAh|ryP MmT0NlQhcA>? NUHwWJpQTE2VTx?= NETuVlZqdmO{ZXHz[YEhfGinIHX4dJJme3Orb36gc4YheHKnY4Xyd49zKG2rUj2xNlVi MU[yOFQ5PDh5MB?=
CD4+ CD25− T  M33ZRmZ2dmO2aX;uJGF{e2G7 M3;CW|EwPSEQvF2= MXfy[YR2[2WVIHfsc4JidCCGTlGgcYV1cHmuYYTpc44> NULZc4tZOjR2N{[zOlA>
BV-173 MnW2RZBweHSxc3nzJGF{e2G7 NFfvPI0xNjJ3L{CuOU8xNjd3L{Gg{txO MVS0PE84Oi97NjDo NYnmZYxUyqCSQmO= Mn\ibY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NH[xS3EzPDR{M{[xNy=>
ML-1 NFrIT3NCeG:ydH;zbZMhSXO|YYm= MYWwMlI2NzBwNT:wMlc2NzFizszN NHPQ[lU1QC95Mj:5OkBp Ml3xxsBRSlN? MYLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MUKyOFQzOzZzMx?=
HL-60 NIDYcVBCeG:ydH;zbZMhSXO|YYm= MV:wMlI2NzBwNT:wMlc2NzFizszN M{G4ZVQ5Nzd{L{m2JIg> MoLGxsBRSlN? M2G4WYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MmnkNlQ1OjN4MUO=
KG-1a MUfBdI9xfG:|aYOgRZN{[Xl? MXiwMlI2NzBwNT:wMlc2NzFizszN MXi0PE84Oi97NjDo MVVCpHBDWw>? MXTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NEDPZ44zPDR{M{[xNy=>
BV-173 M4HKW2Z2dmO2aX;uJGF{e2G7 MXqyOVAwPTBybl2= Mof6OFghcA>? NGL3SFHDqFCEUx?= MojlbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NEexeXYzPDR{M{[xNy=>
CEM NITDeFRHfW6ldHnvckBCe3OjeR?= MYKyOVAwPTBybl2= NGnoXo81QCCq NW\Fc5YzyqCSQmO= MnvSbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NFviUGIzPDR{M{[xNy=>
HL-60 MVXGeY5kfGmxbjDBd5NigQ>? MYqyOVAwPTBybl2= MkLzOFghcA>? NVHzcJJCyqCSQmO= M3:1SIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NWi5VHU2OjR2MkO2NVM>
ML-1 M4DmZ2Z2dmO2aX;uJGF{e2G7 MUeyOVAwPTBybl2= NYG1PHRQPDhiaB?= M2DFZeKhWEKV M2LJRYlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MlrLNlQ1OjN4MUO=
DLD-1 MoexSpVv[3Srb36gRZN{[Xl? MYKyOVAwPTBybl2= MWq0PEBp M3[x[eKhWEKV M{fDS4RwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NFTPSnkzPDR{M{[xNy=>
HCT-116 NHK2bJlHfW6ldHnvckBCe3OjeR?= MVSyOVAwPTBybl2= NELXU4k1QCCq NIju[XfDqFCEUx?= NXOydXhZ\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NF;2cXUzPDR{M{[xNy=>
U937-A/E-9/14/18  NUjmdYMySXCxcITvd4l{KEG|c3H5 NGmybGsxNjBzL{CuNU8yNzFyIN88US=> NWX1[HRHPDhiaB?= NITYTZNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4rCOVI1OzByNEW2
HT29 NXLNRYpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDlbmg4OiCq MV\JR|UxRTF2MEFCtVE4QSEQvF2= MmXXNlQyPzJyNkG=
SW48 M1n5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K5R|czKGh? MV3JR|UxRTF3LkNCtVYvOiEQvF2= NWTLemhSOjRzN{KwOlE>
HCT116 MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTxNVg4OiCq NUTXRpV5UUN3ME2xMlfDuTBwNDFOwG0> MXyyOFE4OjB4MR?=
HepG2 MoHzSpVv[3Srb36gRZN{[Xl? MnfqNE42NzFizszN NITr[YszPCCq NXTmU2ZqTE2VTx?= NXWyRmJnfXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NX\0bopEOjRzNE[4O|Q>
LS174T MonXSpVv[3Srb36gRZN{[Xl? NH7kV2QxNjVxMTFOwG0> MoHqNlQhcA>? MWTEUXNQ NG\rWoRt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> Mkm1NlQyPDZ6N{S=
HepG2 MlzTRZBweHSxc3nzJGF{e2G7 NFPubYIyNzFyL{GwNEDPxE1? M2SzNVch\A>? MWnEUXNQ M2nDTIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWqyOFE1Pjh5NB?=
LS174T Mnf0RZBweHSxc3nzJGF{e2G7 M13rRVEwOTBxMUCwJO69VQ>? NV\Wc4xnPyCm M3KxXmROW09? Mnj0bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2m4clI1OTR4OEe0
QBC-939 NX7MdnhCSXCxcITvd4l{KEG|c3H5 NIXCWIYyNzFyL{GwNEDPxE1? NEjMcFk4KGR? NFywVplFVVOR NGP2b2VqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUDPTWw{OjRzNE[4O|Q>
U251 M3KyUGFxd3C2b4Ppd{BCe3OjeR?= M3jW[lEwOTBxMUCwJO69VQ>? NF:0NHA4KGR? MkixSG1UVw>? NF7zR|dqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NX3Y[4ZkOjRzNE[4O|Q>
HL-60 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;G[YQyKM7:TR?= NH3QNYw1QCCq NVPjb|ZZcW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36= M13tWlI1ODByM{K0
MDA‑MB‑453 Ml\CSpVv[3Srb36gRZN{[Xl? MUiwMlIwOSEQvF2= M2fIUVczKGh? MVvjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= NVnUVWd1OjN6NESyNlg>
HCC1569 NXzCNFRTTnWwY4Tpc44hSXO|YYm= NX;wR3lOOC5{L{Gg{txO NETDeFQ4OiCq MWXjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= NHvWW3ozOzh2NEKyPC=>
BT‑474 NYHYSJVsTnWwY4Tpc44hSXO|YYm= NX7EO4hSOC5{L{Gg{txO M{fzVlczKGh? NEDsXWdk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NUDr[5JPOjN6NESyNlg>
AGS NHrP[XpCeG:ydH;zbZMhSXO|YYm= NUPIfIFzPS9zMD:yNE82OCEQvF2= M{DBc|Q5yqCqwrC= NXnudHpNTE2VTx?= MV\pcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> NEG2T20zOzV6Mke4OC=>
A549 M3\tdWFxd3C2b4Ppd{BCe3OjeR?= M{LyelUwOTBxMkCvOVAh|ryP NYTYdpBWPDkEoHlCpC=> M1\mVWROW09? MX\pcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> MmHoNlM2QDJ5OES=
AGS  MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjxXWg2NzFyL{KwM|UxKM7:TR?= MYm0POKhcMLi MnTXSG1UVw>? NUjwbYZ4cW6mdXPld{BIOi:PIIDoZZNmKGG{cnXzeOKh NYq1d2FYOjN3OEK3PFQ>
Kasumi-1 MVfBdI9xfG:|aYOgRZN{[Xl? NYPPPHl5OC53IN88US=> NXj2RpE5PDkEoHlCpC=> M4fBfYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NHn0OmozOzR7M{O0PC=>
OCI-AML3 M{L0SmFxd3C2b4Ppd{BCe3OjeR?= MYqyMlUh|ryP NYD2dJFxPDkEoHlCpC=> NFj0TmJl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> Mnv2NlM1QTN|NEi=
MV4-11 MYHBdI9xfG:|aYOgRZN{[Xl? M3G5dlIvPSEQvF2= NIjQTlk1QMLiaNMg MXXk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= NILTSm0zOzR7M{O0PC=>
NK  M4\Re2N6fG:2b4jpeJkhSXO|YYm= MlPFNE4xOi1{MDFOwG0> Moj0OUBl NEfTUmRl\WO{ZXHz[ZMhfGinIHP5eI9tgXSrYzDhZ5Rqfmm2eTDv[kBPUyClZXzsd{BifCCrboTldo1m\GmjdHWgZ49v[2WwdILheIlwdnNicnXzeYx1cW6pIHnuJIEhXS2|aHHw[YQh\G:|ZfMAl5Jme3CxboPlJIN2en[n M37t[FI{OzJ6MEi4
NK  MYTBdI9xfG:|aYOgRZN{[Xl? MlXwNE4xOi1{MDFOwG0> MlrwOUBl MXjk[YNz\WG|ZTDOT{Bk\WyuIIDyc4xq\mW{YYTpc44h[W6mII\pZYJqdGm2eTDhd{B1cGViY3;uZ4VvfHKjdHnvckBqdmO{ZXHz[YQ> M{\mdlI{OzJ6MEi4
NK  M{K2OGZ2dmO2aX;uJGF{e2G7 Mk\INE4xOS1{MDFOwG0> NYH6dmtuPSCm NGrDNlVk[XW|ZYOgbJlxd22ndHj5cIF1cW:wIH;mJG5MKGOnbHzzJIlvKGFiZH;z[gKBm3Knc4DvcpNm M{KxdVI{OzJ6MEi4
MOLT4/DNR NE\ZXFZHfW6ldHnvckBCe3OjeR?= MmLMOUDPxE1? MVm0JIQ> M1ztTJJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v Ml3yNlMxPjB3N{C=
Jurkat/DOX M{O1TWZ2dmO2aX;uJGF{e2G7 MWq1JO69VQ>? NYfufZhMPCCm NHP3W4pz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? NXuycVBuOjNyNkC1O|A>
MOLT4/DNR NHzmSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK4OUDPxE1? MVe0JIQ> MXXy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 MoT5NlMxPjB3N{C=
Jurkat/DOX MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfscHNYPSEQvF2= M1rFe|Qh\A>? MUDy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 MmPMNlMxPjB3N{C=
ccRCC  NF;IcY9CeG:ydH;zbZMhSXO|YYm= NEXzUJQxNjBzLUGw{txO NX[2RmxzPzJiaB?= NVH6fm5DTE2VTx?= MXnoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v Mon0NlI5OjZ2Nke=
TNBC  NFPYXWNCeG:ydH;zbZMhSXO|YYm= M4Wzc|AvODFvMUFOwG0> M1:1S|czKGh? NFGwc49FVVOR MWjoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v MkmwNlI5OjZ2Nke=
A498 MoG0RZBweHSxc3nzJGF{e2G7 M2TzWVAvODFvMUFOwG0> Mk\kO|IhcA>? MXrEUXNQ MVnpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MVSyNlgzPjR4Nx?=
KIJ265T NVGwVWN[SXCxcITvd4l{KEG|c3H5 NETaR3IxNjBzLUGw{txO NF74R|g4OiCq NXq4UYQ3TE2VTx?= NEXaOllqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NFfCZYYzOjh{NkS2Oy=>
MDA-231 NV7DdVg1SXCxcITvd4l{KEG|c3H5 NVW0TJNZOC5yMT2xNO69VQ>? M4q2NlczKGh? NICz[GhFVVOR MlXwbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MXmyNlgzPjR4Nx?=
BT-20 MVPBdI9xfG:|aYOgRZN{[Xl? MWewMlAyNTFyzszN NI\Kb|M4OiCq NWDqXmJVTE2VTx?= MX\pcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NEDRSmUzOjh{NkS2Oy=>
U937 M2nwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojTOU0zOCEQvF2= NVixdI9zOjRxNEivO|IhcA>? MVXpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MXeyNlc3PzB{MR?=
HL60 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[1MVIxKM7:TR?= M135WlI1NzR6L{eyJIg> NVHFU|lXcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? Mof3NlI4PjdyMkG=
U937 NYDRS2JJSXCxcITvd4l{KEG|c3H5 NE[3eIMyPSEQvF2= MVKyOE81QC95MjDo M{TlR4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NGK3T3UzOjd4N{CyNS=>
HL60 MWLBdI9xfG:|aYOgRZN{[Xl? M3WxPFE2KM7:TR?= NWe1c5F3OjRxNEivO|IhcA>? MXHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFvHPHIzOjd4N{CyNS=>
LS411N  MYPBdI9xfG:|aYOgRZN{[Xl? MUmwMlUh|ryP NWfRTWVQPzJiaB?= M2TGN4lv[3KnYYPld{BH[XNibWLORUBt\X[nbB?= MVyyNlQ3OTZ7NR?=
MDA-MB-231 NH\1SppCeG:ydH;zbZMhSXO|YYm= M1HVPFExKM7:TR?= MnPjOFghcA>? M3X2[JJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmjVNlE5QDd4OUe=
MCF-7  MVXBdI9xfG:|aYOgRZN{[Xl? NF;XNGsyOCEQvF2= MVm0PEBp NYr2OXdRemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Ml:wNlE5QDd4OUe=
A375 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPBXG01OC53IN88US=> NHO2OVQyNzVxODDk NF\me|ZqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= Ml;SNlE4QTZ4MkK=
SKMEL1 NXzsbJpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES3dGkxNjVizszN MUixM|UwQCCm NIr0fYpqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MWSyNVc6PjZ{Mh?=
SKMEL3 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDQNE42KM7:TR?= M3zEUVEwPS96IHS= MUjpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? Mo\CNlE4QTZ4MkK=
SKMEL28 NH20Wm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCwMlUh|ryP NGrlVlIyNzVxODDk MnjLbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MWmyNVc6PjZ{Mh?=
MeWo MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmwMlUh|ryP M1v6VVEwPS96IHS= NVq0PYwycW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= M4HUVFIyPzl4NkKy
B16 NG\kWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrDNo0xNjVizszN NGjQWI8yNzVxODDk MVTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? Ml3tNlE4QTZ4MkK=
Ly 1 NX76[Hd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmyOEBp MmnJTWM2OD15LkOg{txO MV:yNVc4OjB2OR?=
Ly 7 NIHvOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fhdFI1KGh? MmLZTWM2OD1zMD63JO69VQ>? NI\3dWYzOTd5MkC0PS=>
Su-DHL6 M4rRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjDRXUzPCCq MlrlTWM2OO,:nkKwJO69VQ>? NYHjSmYxOjF5N{KwOFk>
Ly 10 NUftfVFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rpflI1KGh? M2jKXWlEPTExvK6yNEDPxE1? MVeyNVc4OjB2OR?=
RIVA MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7UeVE2OjRiaB?= NEjmdVZKSzVy78{eNlAh|ryP M4LlPFIyPzd{MES5
Su-DHL2 M4mzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\Xc3YzPCCq NF7FNFBKSzVy78{eNlAh|ryP MWKyNVc4OjB2OR?=
Ly 1 NFjm[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HsV|Q5KGh? MmexTWM2OD1yLkO0JO69VQ>? MWeyNVc4OjB2OR?=
Ly 7 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fIclQ5KGh? NXnZTHNoUUN3ME2wMlAzPSEQvF2= NWnH[2ZHOjF5N{KwOFk>
Su-DHL6 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TWfFQ5KGh? NEnBfI5KSzVy78{eNlAh|ryP M1vONFIyPzd{MES5
Ly 10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfxe5E5PDhiaB?= NHn5TJJKSzVyPUGuPEDPxE1? M{X6VlIyPzd{MES5
RIVA NVX4dWpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWS0PEBp MUfJR|Ux97zgMkCg{txO MW[yNVc4OjB2OR?=
Su-DHL2 M3LkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rKRlQ5KGh? NVnRO5RLUUN3ME2xO{41KM7:TR?= MUiyNVc4OjB2OR?=
Ly 1 NXewdIt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml25O|IhcA>? MUPJR|UxRTBwMEGg{txO M1niXVIyPzd{MES5
Ly 7 M{TNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O1dlczKGh? MkHFTWM2OD1yLkCxPEDPxE1? M2PtPVIyPzd{MES5
Su-DHL6 MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfhdnQ4OiCq NFrud5dKSzVyPUGuOkDPxE1? MnGwNlE4PzJyNEm=
Ly 10 M1Hi[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P5XVczKGh? MlrYTWM2OD1zLkKg{txO NEDvOGUzOTd5MkC0PS=>
RIVA MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W2NFczKGh? Mn2yTWM2OO,:nkKwJO69VQ>? NVrhUFZ1OjF5N{KwOFk>
Su-DHL2 M2HFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HKb|czKGh? MWjJR|UxRTFzLkKg{txO NX\ieZBrOjF5N{KwOFk>

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03709550 Not yet recruiting Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma in the Soft Tissue|Prostate Carcinoma Metastatic in the Bone|PSA Level Greater Than or Equal to Two|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 Roswell Park Cancer Institute|National Cancer Institute (NCI) November 30 2018 Phase 1|Phase 2
NCT03691376 Not yet recruiting HLA-A*0201 Positive Cells Present|HLA-DP4 Positive Cells Present|Platinum-Resistant Ovarian Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Fallopian Tube Carcinoma|Refractory Ovarian Carcinoma|Refractory Primary Peritoneal Carcinoma Roswell Park Cancer Institute|National Cancer Institute (NCI) November 25 2018 Phase 1
NCT03661307 Recruiting Acute Myeloid Leukemia With FLT3/ITD Mutation|Blasts More Than 10 Percent of Bone Marrow Nucleated Cells|Blasts More Than 10 Percent of Peripheral Blood White Cells|Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Myelodysplastic Syndrome M.D. Anderson Cancer Center|National Cancer Institute (NCI) October 31 2018 Phase 1|Phase 2
NCT03679650 Recruiting Acute Myelogenous Leukemia Dana-Farber Cancer Institute|National Cancer Institute (NCI) October 11 2018 Phase 1
NCT03252457 Not yet recruiting Purpura Thrombocytopenic Idiopathic|Immune Thrombocytopenia Shandong University|Second Affiliated Hospital of Medical College Shandong University|Shandong Provincial Hospital|Qingdao Central Hospital|Chinese Academy of Medical Sciences September 1 2018 Phase 3
NCT03593915 Recruiting Myelodysplastic Syndromes (MDS) Tolero Pharmaceuticals Inc. August 29 2018 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID